Sino Biological Launches XPressMAX™ Cell-Free Protein Synthesis Kit to Accelerate AI-Powered Antibody Drug Discovery

Sino Biological, Inc. (Shenzhen Stock Exchange: 301047.SZ) has announced the launch of the XPressMAX™ Cell-Free Protein Synthesis Kit (Cat#: CFKIT02), a new product aimed at accelerating artificial intelligence (AI)-powered high-throughput screening for antibody drug discovery. The kit uses advanced cell-free protein synthesis technology to produce target proteins and antibodies in vitro, bypassing the limitations of traditional cell-based expression systems.

According to the company, the kit is based on an E. coli lysate and is fully supplemented with essential transcription and translation components, enabling direct protein synthesis from plasmid or PCR templates. It is designed specifically for antibody drug discovery and supports rapid expression and validation of VHH, scFv, Fab, and Miniprotein. Sino Biological has established a high-throughput cell-free expression platform that validates over 2,000 scFv/VHH molecules in 3-4 weeks, matching AI's rapid iteration pace.

Key highlights of the XPressMAX™ kit include ultra-fast synthesis completed in just 3 hours, a success rate greater than 99%, and support for complex disulfide bonding, which ensures native folding and bioactivity without additional enhancers. Dr. Rob Burgess, Chief Business Officer at Sino Biological US, Inc., stated, "Our XPressMAX™ is a significant advancement in research tools and reagents for next-generation therapeutic discovery. By combining rapid, reliable protein expression with intelligent screening, we are helping our partners compress antibody discovery timelines without compromising quality."

Dr. Jie Zhang, Sino Biological's General Manager, added, "AI is revolutionizing antibody screening, but it demands expression systems that can match its speed and throughput. XPressMAX™ achieves rapid, high-success expression of challenging proteins in as little as 3 hours." The implications of this announcement are substantial: by integrating with AI-powered screening platforms, the kit can dramatically reduce both development timelines and costs, potentially accelerating the discovery of new antibody therapeutics for various diseases.

Researchers can visit Sino Biological's product page for more information or request a free sample. The company also offers a sample request form for interested parties. Sino Biological, an international reagent supplier and CRO service provider, specializes in recombinant protein production and antibody development, with facilities in the US and Canada serving researchers in over 90 countries.